Vivos Inc Summarizes Progress in its Animal Therapy Division

Core Insights - Vivos Inc.'s IsoPet division experienced a remarkable 1,200% year-over-year increase in administered therapies from 2024 to 2025, indicating a significant rise in veterinary adoption and demand for IsoPet therapy [1] - The company is implementing profitability-focused initiatives starting in Q1 2026 while expanding its network of certified clinics [1] Expansion of Services - Over 100 IsoPet treatments have been successfully performed on various animals, including dogs, cats, horses, and exotic animals [2] - Sun City Veterinary Surgery Center in El Paso, Texas, has become the first companion animal hospital in Texas certified to offer IsoPet therapy, enhancing access to advanced cancer treatment for pets in the region [3][4] - The University of Florida Small Animal Hospital has also been certified to provide IsoPet therapy, making it one of the few academic veterinary centers to offer this service for both small and large animals [5][6] Clinical Outcomes and Research - Seventeen patients were treated in November and thirteen in December, marking an all-time high for the IsoPet division [7] - The completion of case study therapies is expected to lead to multiple publications in 2026, which will aid in marketing efforts to veterinarians and oncologists [7] - A strategic partnership with Exubrion Therapeutics aims to co-market IsoPet in the equine oncology segment, which is identified as a high-growth opportunity [8]